X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.biospace.com/article/fda-rejects-viatris-mapi-s-long-acting-multiple-sclerosis-injection/
https://www.fiercepharma.com/pharma/teva-granted-rare-pre-trial-appeal-10b-kickbacks-case-holding-trial
https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-drugs-dont-make-whos-essential-list-ebola-ms-drugs-added-2023-07-26/
https://www.europeanpharmaceuticalreview.com/news/177879/stem-cell-transplants-may-slow-disability-progression-in-ms/
https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-caregivers-and-health-care-providers-cross-compatibility-issues-autoinjector
https://www.fiercepharma.com/pharma/teva-faces-100m-lawsuit-israel-over-unpaid-copaxone-royalties-report
https://www.fiercepharma.com/pharma/teva-s-austedo-struggling-from-pandemic-slowdown-needs-huge-gains-to-meet-company-s-2021
https://en.globes.co.il/en/article-court-denies-tevas-motion-to-dismiss-copaxone-kickbacks-case-1001384395
https://www.fiercepharma.com/pharma/uninhibited-price-hikes-lobbying-and-profit-driven-copay-assistance-congressional-probe
https://www.fiercepharma.com/pharma/teva-faces-generics-price-fixing-charges-after-walking-away-from-settlement-offer
http://www.pharmatimes.com/news/hancock_confirms_replacement_of_public_health_england_1347010
https://www.raps.org/news-and-articles/news-articles/2020/8/us-sues-teva-over-copaxone-co-pay-assistance-schem
https://www.contractpharma.com/contents/view_breaking-news/2020-06-15/mapi-pharma-mylan-expand-ms-alliance/
https://www.fiercepharma.com/pharma/teva-walks-away-from-price-fixing-settlement-talks-amid-covid-19-chaos-report
https://en.globes.co.il/en/article-teva-asks-fda-to-define-copaxone-as-biologics-drug-1001319876
https://www.raps.org/news-and-articles/news-articles/2020/2/teva-calls-on-fda-to-make-copaxone-a-biologic-as-p
http://www.pmlive.com/pharma_news/tevas_weak_pipeline_hit_by_tourettes_drug_trial_failure_1326565
https://en.globes.co.il/en/article-teva-to-pay-54m-to-settle-copaxone-bribery-case-in-us-1001313846
https://www.biopharmadive.com/news/teva-5-updates-third-quarter-earnings-debt-cash-flow-ajovy-copaxone/566836/
https://www.biopharmadive.com/news/multiple-sclerosis-drug-costs-skyrocketed-for-medicare-and-patients-study/561757/
https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-lowest-paid-indian-pharma-ceo-dr-reddy-s-crl-natco-s-double-whammy
https://www.fiercepharma.com/manufacturing/dr-reddy-s-copaxone-nuvaring-generics-derailed-by-fda
https://www.in-pharmatechnologist.com/Article/2019/07/30/Mapi-builds-manufacturing-plant-for-GA-Depot
https://www.fiercepharma.com/pharma-asia/foreign-drugmakers-under-threat-as-china-rolls-out-drug-list-to-boost-generic
http://www.pmlive.com/pharma_news/biogen_trumpets_safety_data_for_tecfidera_follow-up_1289548
https://endpts.com/revenue-plunges-stock-takes-a-drubbing-but-teva-ceo-kare-schultz-still-grabs-32-5m-in-chart-topping-compensation/
https://www.npr.org/sections/health-shots/2019/03/27/706730906/medicares-uncapped-drug-costs-take-a-big-bite-from-already-tight-budgets?utm_medium=RSS&utm_campaign=health
https://www.cnbc.com/2019/02/27/reuters-america-mylan-shares-sink-as-bleak-profit-outlook-sparks-growth-concerns.html
https://www.fiercepharma.com/pharma/teva-forecasts-worse-than-expected-trough-year-as-generics-hammer-ms-drug-copaxone
https://www.fiercepharma.com/pharma/jpm-wrapup-must-reads-from-a-week-biopharma-news-chosen-by-you
https://www.haaretz.com/israel-news/business/business-in-brief-teva-threatened-with-strike-at-main-plant-for-making-top-selling-1.6822355
https://www.fiercepharma.com/pharma/teva-hit-6-3m-verdict-age-anti-american-discrimination-suit
https://www.forbes.com/sites/joshuacohen/2018/11/12/specialty-generics-barriers-to-uptake/#5edb946b576f
https://www.biopharmadive.com/news/mylans-generic-copaxone-wins-in-court-but-market-barriers-remain/539666/
https://www.fiercepharma.com/pharma/facing-generics-from-mylan-and-novartis-teva-loses-patent-appeal-copaxone
https://www.reuters.com/article/us-teva-mylan-patent/u-s-appeals-court-upholds-ruling-that-canceled-teva-copaxone-patents-idUSKCN1MM1V9
https://www.moneycontrol.com/news/business/companies/natcos-partner-mylan-prevails-over-teva-in-copaxone-patent-litigation-3042791.html
https://www.drugdevelopment-technology.com/news/novartis-reports-positive-topline-data-phase-iiib-trial-gilenya/
https://www.fiercepharma.com/pharma/novartis-gilenya-tops-teva-giant-copaxone-head-to-head-ms-study
https://www.fiercepharma.com/pharma/novartis-gilenya-tops-teva-giant-copaxone-head-to-head-ms-study
https://www.fiercepharma.com/pharma/novartis-gilenya-tops-teva-giant-copaxone-head-to-head-ms-study
https://www.businesswire.com/news/home/20181010005336/en/Teva-Presents-25-year-Safety-Data-Longest-Continuous
https://www.fiercepharma.com/pharma/was-last-week-s-teva-sell-off-warranted-depends-who-you-ask
https://www.biopharmadive.com/news/teva-wins-much-needed-us-approval-migraine-drug-ajovy/532422/
Market Place
Share 
